Wednesday, July 11, 2018

FDA responds on behalf of chronic pain patients who require opioids to treat their pain

As I said in my June blog, if we want change, we are obliged to share our 
unique individual circumstances and our life encounters. If you have been affected by having your opioids restricted, if you want pain management that fits within your personal framework, it’s time to use your voice.

Hope has turned in to reality; the FDA is listening! 
Our voice is being heard, so let’s keep using it.

ID: FDA-2018-N-1621-0001
The Food and Drug Administration (FDA)

“Patient-Focused Drug Development for Chronic Pain.” The public meeting will provide patients (including adult and pediatric patients) with an opportunity to present to FDA their perspectives on the impacts of chronic pain, views on treatment approaches for chronic pain, and challenges or barriers to accessing treatments. FDA is particularly interested in hearing from patients who experience chronic pain that is managed with analgesic medications such as opioids, acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), antidepressants; other medications; and non-pharmacologic interventions or therapies.

Comment Now!
Due Sep 10 2018, at 11:59 PM ET

Adversity is only an obstacle if we fail to see opportunity."

Additional Reading:

Opportunity Knocks Again: Public Comments on Patient-Focused Drug Development for Chronic Pain (includes my comment)

In healing,

Celeste Cooper, RN / Author, Freelancer, Advocate

Think adversity?-See opportunity!

~ • ~ • ~ • ~ • ~ • ~

Learn more about Celeste’s books here. Subscribe to posts by using the information in the upper right hand corner or use the share buttons to share with others. 

No comments:

Celeste's Website

Celeste's Website
Click on the picture